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MAIN POINTS 
 Milder infections such as acute sinusitis, acute bronchitis and uncomplicated UTI are common
indications for systemic fluoroquinolone therapy in Europe.
 Although fluoroquinolone prescribing has fallen in France, Germany and UK, trends appear to
vary by country and by indication.
This is a post-peer-review, pre-copyedit version of an article published in Clinical Drug Investigation. The final 
authenticated version is available online at: http://dx.doi.org/10.1007/s40261-018-0684-7
  
ABSTRACT 
Background and Objectives 
In the United States the benefit-risk profile of fluoroquinolones for treating patients with 
acute bacterial sinusitis, acute bacterial exacerbation of chronic bronchitis, and 
uncomplicated urinary tract infections (uUTI) is considered unfavorable. However, the 
number of fluoroquinolone products in the EU indicated and prescribed for these infections 
is uncertain. The objective was to provide data on indications for fluoroquinolones in 
Europe and examine the prevalence of prescribing in France, Germany and the UK. 
Method 
Descriptive analysis of indications for systemic fluoroquinolone antibiotic across the 
European Economic Area (EEA) and descriptive analysis of systemic fluoroquinolone 
antibiotic prescribing in France, Germany and UK electronic health records (2000-2015). 
Results 
All EEA countries had fluoroquinolone products indicated for acute sinusitis, acute 
bronchitis or uUTI, with differences in the number of products between countries for: acute 
sinusitis (19.5%-51.9%); acute bronchitis (22.2%-73.4%); and uUTI (52.0%-89.1%). 
The prevalence of fluoroquinolone prescribing for the treatment of respiratory tract 
infections (RTI) appeared to fall with time in all countries and for UTI in France and UK 
only. Changes were greatest in the UK. In France, Germany and the UK respectively: acute 
sinusitis accounted for 29.5%, 20.6% and 40.7% of all oral fluoroquinolone prescriptions 
for upper RTIs; acute bronchitis accounted for 63.0%, 83.0% and 89.9% of all 
fluoroquinolone prescriptions for lower RTIs; uUTI accounted for 83.3%, 89.9%, 32.2% of 
all fluoroquinolone prescriptions for UTIs.  
Conclusion 
Large numbers of fluoroquinolone products in Europe are listed for the treatment of milder 
infections such as acute bronchitis, acute sinusitis and uUTI. Among the countries 
assessed, fluoroquinolones were commonly prescribed for these conditions and potentially 
should lead to a review of therapeutic guidelines. 
 
  
1. INTRODUCTION 
Fluoroquinolone antibiotics inhibit type II topoisomerases required for bacterial DNA 
replication, transcription and repair.[1] They are widely prescribed treatments for a broad 
range of infections including those affecting the urinary, respiratory and gastrointestinal 
systems. Due to their broad spectrum of activity they are effective against a wide range 
of infections. However, as with most medicines fluoroquinolones have the potential to 
cause adverse reactions, which may be persistent in some patients. Adverse reactions 
from systemic fluoroquinolone exposure may involve tendons, muscles, joints and nerves, 
and may include reactions such as tendon rupture, peripheral neuropathy and 
neuropsychiatric reactions.[2-8] Furthermore, there have been increasing concerns over 
antimicrobial resistance resulting from antibiotic prescribing with resistance rates 
displaying wide variations in Europe depending on the bacterial species, antimicrobial 
group and geographical region.[9] The benefit-risk profile for the use of systemic 
fluoroquinolone antibiotics may differ for less severe infections such as those with and 
without complicated infections, for example cystitis and pyelonephritis.  
 
These concerns have resulted in the European Medicines Agency reviewing the persistence 
of side effects known to occur with fluoroquinolone antibiotics.[10] Data are therefore 
required on patterns of fluoroquinolone use, particular for these less severe indications. A 
United States (U.S.) Food and Drug Administration (FDA) safety review using evidence 
from prescribing data, published literature and the FDA’s Adverse Events Reporting 
System previously concluded that fluoroquinolone antibiotics may be associated with 
potentially long-term serious side effects when administered via systemic routes of 
administration (i.e. tablets, capsules, and intravenous formulations).[11] In May 2016, 
the FDA advised that because of the potential for long-term serious adverse reactions, the 
benefit-risk profile of fluoroquinolones for treating patients with acute bacterial sinusitis, 
acute bacterial exacerbation of chronic bronchitis, and uncomplicated urinary tract 
infections (uUTI) was unfavorable.[12] It was decided by the FDA that fluoroquinolones 
should not be prescribed for these indications unless no other alternatives are available 
  
and that the product labels and medication guides for all fluoroquinolone antibacterial 
drugs be updated in the U.S. to reflect new safety information. Off-label use of systemic 
fluoroquinolone antibiotics may also occur, the extent of which may vary between country. 
The aim of this study was to provide data on potential indications for systemic 
fluoroquinolone products authorized in Europe with an emphasis on acute sinusitis, acute 
bronchitis and uUTI and to examine the prevalence of fluoroquinolone prescribing for these 
conditions in France, Germany and the UK. 
 
2. METHODS 
Data sources 
Article 57 database 
The European Medicines Agency (EMA) Article 57 database contains information on all 
medicinal products for human use in Europe, which marketing authorisation holders are 
required to submit and is based upon the content of their Summary of Product 
Characteristics (SPCs).[13] The Article 57 database is considered around 97% complete 
as determined through comparison with national databases in a study conducted by the 
European Medicines Agency. Products are recorded per country and contain descriptions 
of indications for use for that product in that country. 
 
Databases 
A full description of each database in contained within supplementary file. In brief the 
IMS® Disease Analyzer France and Germany (versions June 2016) databases contain 
anonymised electronic primary care electronic medical record data on diagnoses (coded 
using the International Classification of Disease (ICD) coding system) and prescriptions 
from a representative panel of general practitioners (GPs) from each country commencing 
from 1997 and 1992 respectively. Data are representative in terms of age, gender and 
geographical distribution. The UK THIN database (version May 2016) contains electronic 
primary care medical records extracted from general practices covering approximately 6% 
of the UK population. Data are representative of the UK population in terms of age, 
  
deprivation, and geographical distribution. Diagnoses, symptoms, and other relevant 
health information are recorded using the Read Code clinical classification system, a 
hierarchical classification system.  
 
Populations 
Patients were included from the IMS® Disease Analyzer France and Germany cohort if they 
had a consultation date between the start and end of the study period (01.01.2000 and 
31.12.2015 respectively) with cohort start determined by the date of the first recording; 
all patients with a consultation during the year were used as population denominator. For 
the UK database, cohort entry was defined as the latest of the following dates: start of the 
study period (01.01.2000); or date of registration with a general practice. Cohort exit was 
defined by the earliest of the following dates: deregistration from the general practice; 
death; date of last electronic data collection; end of the study period (31.12.2015). 
  
Exposures 
In the IMS® Disease Analyzer France and Germany databases, prescriptions for incident 
fluoroquinolones were identified by EphMRA ATC code J01G1 (non-topical fluoroquinolone 
administration) and by gemscript codes in the UK. Only incident fluoroquinolone 
prescription episodes were evaluated, defined as a prescription for a systemic 
fluoroquinolone with no prescription in the previous 30 days. In the UK, incident 
fluoroquinolones were predominantly prescribed second line whilst in France and Germany 
there was a higher proportion of first line use. Please refer to the supplementary material 
for further methodological details.  
 
Fluoroquinolone indications 
Indications were identified from the Article 57 database by searching disease descriptions 
for each fluoroquinolone product. Clinical indications were identified in the electronic 
medical record databases by identifying ICD10 and Read codes recorded in people 
prescribed a systemic fluoroquinolone antibiotic. Disease descriptions and codes were first 
  
broadly categorised into the following pre-specified groups based upon a scoping exercise: 
upper respiratory tract infections (URTI); lower respiratory tract infections (LRTI); urinary 
tract infections (UTI); ear infections; gastrointestinal infections (including hepatobiliary 
infections); genital infections (excluding testicular and prostatic infections considered 
separately); testicular infections; prostatic infections; skin and soft tissue infections; bone 
infections; and other indications. Codes that could not be readily grouped into one of the 
above categories were considered as unclassified. Codes were screened by two reviewers, 
with a third reviewer used to reach consensus if needed. For upper respiratory tract 
infections (URTI), lower respiratory tract infections (LRTI) and urinary tract infections 
(UTI), indications were then categorised into acute sinusitis, acute bronchitis and uUTIs 
as described in the supplementary material.  
 
Analysis 
A descriptive analysis of indications for treatment with systemic fluoroquinolone products 
in the Article 57 database was undertaken for each country in the EEA. The prevalence of 
incident systemic fluoroquinolone prescribing in France, Germany and the UK was 
calculated for each indication category as a percentage of the total number of incident 
fluoroquinolone prescriptions identified with a systemic route of administration. The 
descriptive analysis of indications recorded in the Article 57 database was then compared 
to clinical indications through routine electronic prescribing for France, Germany and the 
UK with yearly trends in the prevalence of fluoroquinolone prescribing plotted. In a post-
hoc analysis, Joinpoint regression using the grid search method and permutation testing 
for model selection was used to determine at what point statistically significant changes 
in trend occurred in each country for uUTI, acute bronchitis and acute sinusitis.(13) All 
analyses contained within this study are based on “own calculation” (i.e. analysis was 
conducted by the study authors and not by the database providers). The study was 
registered in the EU register of post-authorization studies (number EUPAS20889). 
  
 
3. RESULTS 
Listed indications for treatment with fluoroquinolones in Europe 
The Article 57 database contained a total of 2694 fluoroquinolone product entries across 
30 EEA countries of which 2353 had a systemic routes of administration (1762 (74.9%) 
oral; 591 (25.1%) intravenous). The most frequently recorded fluoroquinolone active 
substances were ciprofloxacin (45.3%), levofloxacin (26.4%), moxifloxacin (12.4%), 
ofloxacin (9.0%) and norfloxacin (3.6%) (supplementary table 2). 
 
These 2694 product entries contained a sum total of 36830 indication descriptions (mean 
13.7 per product). All EEA countries had one or more fluoroquinolone product with 
indicated for the treatment of acute sinusitis, acute bronchitis and uUTI that varied 
according to the type of active substance, with norfloxacin licenced for uUTI only 
(supplementary table 3). This ranged from: 19.5% to 51.9% for acute sinusitis; 22.2% to 
73.4% for acute bronchitis; and 52.0% to 89.1% for uUTI (table 1).  
 
Prevalence of fluoroquinolone prescribing in France, Germany and the UK  
The most frequently prescribed fluoroquinolone in France was norfloxacin (26.9%) with 
ciprofloxacin more commonly prescribed in Germany (51.0%) and in the UK (89.4%) 
(supplementary table 4). Clinical indications were identified in 70.1%, 83.5% and 62.1% 
of incident fluoroquinolone prescriptions from the French, German and UK databases 
respectively. The most frequent indication for fluoroquinolone treatment in France, 
Germany and the UK was for UTI (58.7%, 43.4% and 33.5% respectively). Figure 1 shows 
the proportion of incident fluoroquinolone prescriptions for the treatment of LRTI, URTI 
and UTI along with the subset of milder infections of acute bronchitis, acute sinusitis and 
uncomplicated UTI in France, Germany and the UK. Fluoroquinolones were prescribed for 
the treatment of acute bronchitis, acute sinusitis and uUTI in: 10.0%, 4.7% and 48.9% of 
instances respectively in France; in 29.9%, 3.4% and 39.0% of instances respectively in 
Germany; and in 3.7%, 1.7% and 19.9% of instances respectively in the UK. Figure 2 
  
shows the proportion of incident fluoroquinolone prescriptions for the treatment of the 
remaining indication categories in France, Germany and the UK. The proportion of incident 
fluoroquinolone prescriptions for different indications varied by substance within each 
country, with levofloxacin and moxifloxacin mainly being used for the treatment of URTI 
and LRTI, whilst norfloxacin and ofloxacin was mainly use for the treatment of UTI 
(supplementary tables 5-7, supplementary figure 1). 
 
Trends in systemic fluoroquinolone prescribing in France, Germany and the UK 
Trends in systemic fluoroquinolone prescribing are shown in figure 2. There were rising 
trends in fluoroquinolone prescribing until 2007 in France and UK, and 2009 in Germany. 
Fluoroquinolone prescribing then fell in France and the UK for, particularly for the 
treatment of LRTI, URTI and UTIs whilst in Germany changes were smaller and for UTI 
remained relatively stable. In absolute terms the numbers of fluoroquinolone prescriptions 
for indications other than for RTI and UTI were small. Similar trends in fluoroquinolone 
prescribing for the treatment of acute bronchitis, acute sinusitis and uUTI are shown in 
figure 3. Of the three indications, uUTI was the most common indication for 
fluoroquinolone prescribing in all three countries. In France there were significant changes 
in trend in 2006 and 2014 for uUTI, and in 2004 and 2009 for acute bronchitis and acute 
sinusitis. In Germany, there were significant changes in trend in 2005 and 2010 for uUTI, 
2005 for acute bronchitis and in 2005 and 2013 for acute sinusitis. In the UK, there were 
significant changes in trend in 2007 and 2011 for uUTI, and in 2007 and 2012 for acute 
bronchitis and acute sinusitis (supplementary table 8).  
 
Comparisons between listed indications and those in clinical practice demonstrated that 
apart from ciprofloxacin, all other fluoroquinolone active substance were prescribed to 
treat infections in a greater number of indication categories than listed suggesting off-
label use although in absolute terms some of this usage was small. 
 
 
  
4. DISCUSSION 
In light of recent decisions in the U.S. on the use of fluoroquinolone antibiotics for the 
treatment of acute sinusitis, acute bronchitis and uUTI, we performed a descriptive 
analysis of listed indications for treatment with systemic fluoroquinolone products across 
the EEA and examined the prevalence of fluoroquinolone prescribing in France, Germany 
and the UK. This study found that fluoroquinolone products across the EEA are frequently 
indicated for the treatment of acute sinusitis, acute bronchitis and uUTI, the extent of 
which appeared to vary by country and by fluoroquinolone active substance. 
Fluoroquinolones were also prescribed for these milder infections in France, Germany and 
the UK with some evidence of off-label use to treat infections in other systems. Although 
the prevalence of fluoroquinolone prescribing has fallen over recent years, variation in 
changes occurred by country and by indication, with trends in fluoroquinolone prescribing 
for the treatment of UTIs in Germany remaining fairly stable. 
 
Although a large percentage of fluoroquinolone products across the EEA had a listed 
indication related to the recent FDA safety communication, it is perhaps not the number 
of products but how fluoroquinolones are prescribed in clinical practice which is more 
important. This study shows that compared with France and Germany, fluoroquinolone 
prescribing has fallen more steeply in the UK since 2008, which may be related to antibiotic 
stewardship interventions and changes in antibiotic guidelines in response to tackling 
Clostridium difficile infection.[15, 16] This has important implications in reducing antibiotic 
resistance which may result in treatment failure and delays in clinical recovery after 
treatment with antibiotics, however high quality trials for clinician-targeted interventions 
to influence antibiotic prescribing behaviour for respiratory tract infections in primary care 
may still be required to provide robust evidence of their comparative effectiveness.[17, 
18] 
 
Overall, the most common indication for fluoroquinolones was for the treatment of UTI. 
However, at substance level levofloxacin and moxifloxacin were more commonly used to 
  
treat LRTIs with norfloxacin being the most commonly prescribed fluoroquinolone in France 
compared to ciprofloxacin in the UK and Germany. This is also important because the 
benefit-risk for fluoroquinolone antibiotics will not only on depend upon the severity of 
infections but also on the comparable safety of different fluoroquinolone active substances. 
Fluoroquinolones where prescribed for the treatment of URTI in France and Germany more 
often than in the UK where prescribing for the treatment of GI infections was more 
common. In relative terms, acute bronchitis appeared to account for 66.9% and 53.6% of 
all fluoroquinolones prescribed for the treatment of LRTIs in Germany and France 
compared to only 7.6% in the UK. Similarly, uUTI appeared to account for 89.9% and 
83.3% of all fluoroquinolone prescribing for the treatment of UTIs in Germany and France 
compared to 59.5% in the UK.  
 
Variation in prescribing is important and there are several potential factors that may 
influence the use of fluoroquinolone antibiotics including clinical guidelines, local drug 
formularies, and differences in prescribing culture. For example, a study of 
recommendations for empiric first-choice antibiotic treatment of uUTIs in six European 
countries found considerable differences in recommendation and most countries offered 
more than one first-choice antibiotic, with nitrofurantoin being listed as an option in five 
countries and fluoroquinolones in one country only.[19] In our study, fluoroquinolones 
were more often prescribed as first-line therapy in France and Germany than in the UK.  
Antimicrobial resistance rates display wide variations in Europe depending on the bacterial 
species, antimicrobial group and geographical region.[9] In general, lower resistance rates 
have been reported by northern European countries compared to southern European 
countries that are considered likely related to variations in antimicrobial use, infection 
prevention and control practices, and dissimilarities in diagnostic and healthcare utilisation 
patterns in the countries. Antimicrobial resistance can result from antimicrobial use but 
may also drive the choice of different antibiotics that may explain some of the differences 
observed in our study. However, we analysed data from France, Germany and the UK only 
because we had access to these databases. Although differences in the first-choice 
  
antibiotic may depend upon different factors such as the local patterns of bacterial 
resistance, they are perhaps less likely to be a factor in deciding between different 
fluoroquinolones. In a qualitative study exploring reasons to prescribe fluoroquinolone 
antibiotics, interviews were conducted among GPs from high and average fluoroquinolone 
prescribing practices in the UK.[20]This study found that prescribing fluoroquinolone 
antibiotics, as opposed to  narrow-spectrum antibiotics, depended upon several clinical 
considerations, perceptions of patient expectations and organizational influences including 
prioritising patient needs and considering long term consequences. Understanding 
variation in the choice of fluoroquinolone antibiotic prescribed is also important because 
they may have different properties and it cannot be assumed that all fluoroquinolones are 
equally effective or equally safe.  
 
Fluoroquinolones may cause serious adverse reactions including peripheral neuropathy, 
tendinopathies and psychiatric reactions.[2-7] Factors to consider when assessing their 
benefit risk may include overall effectiveness, the frequency and severity of infections 
treated with fluoroquinolones and the frequency and severity of adverse effects. Bacterial 
infections such as acute sinusitis, acute bronchitis and uUTI are common and can be 
relatively mild. There is also the potential for misdiagnosis of viral causes for sinusitis and 
bronchitis. Part of assessing benefit risk may also depend upon whether these drugs are 
used first- or second-line. In this regard, it was recently noted in an editorial that antibiotic 
stewardship programmes may help to reduce inappropriate use of fluoroquinolone 
prescribing and indeed variation, and by improving the level of knowledge of antibiotics 
among community prescribers is required particularly with increasing antibiotic resistance 
in health care settings.[21]. 
 
This study has several limitations. First, the definitions of acute bronchitis, acute sinusitis 
and uUTI used in this study were based on definitions which included unspecified, 
conditions (bronchitis and UTI) which potential could introduce some misclassification. 
However, codes for sinusitis and UTI are commonly recorded in primary care records and 
  
it is likely many will be for acute and uncomplicated infections respectively based upon 
our primary care experience. Second, identifying clinical indications in the electronic 
medical records relied upon screening of codes using a look-back period because clinical 
indications were not routinely linked to the prescription. However, we carefully tailored 
our look-back periods based upon the frequency of codes and coding practices observed 
within each database. Despite this, we cannot confirm the indication with either the patient 
or the health care professional that would ideally be required to undergo proper validation. 
Lastly, we used only broad high-level indication categories rather than disease-specific 
indications as these were considered too extensive to analyse and report, particularly when 
our focus specifically related to sinusitis, bronchitis and uUTI. In this regard, significant 
variation in prescribing is likely to exist within indication categories, the extent of which is 
uncertain. 
 
CONCLUSION 
In conclusion, many fluoroquinolones products with a systemic route of administration 
across the EEA appear to have an indication for the treatment of milder infections including 
acute sinusitis, acute bronchitis or uUTI. In clinical practice, fluoroquinolones are not 
infrequently prescribed for these indications which may have implications for clinical 
guidelines, and antibiotic stewardship interventions. 
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Table 1. Percentage of systemic fluoroquinolone products with an indication for acute 
sinusitis, acute bronchitis or uncomplicated UTI in each EEA country. 
 
 
Country 
 
Number of  
products 
 
Acute 
Sinusitis 
(%) 
 
Acute 
Bronchitis 
(%) 
 
Uncomplicated 
UTI  
(%) 
Austria 102 29.4 59.8 68.6 
Belgium 167 36.5 41.3 71.3 
Bulgaria 76 39.5 54.0 69.8 
Croatia 42 26.2 59.5 59.5 
Cyprus 62 35.5 48.4 80.7 
Czech Republic 41 19.5 39.0 58.5 
Denmark 50 24.0 50.0 52.0 
Estonia 35 37.1 68.6 71.4 
Finland 51 25.5 54.9 60.8 
France 141 27.0 49.7 73.1 
Germany 236 32.6 53.0 69.9 
Greece 135 20.0 28.2 79.3 
Hungary 79 51.9 65.8 70.9 
Iceland 18 34.6 65.5 89.1 
Ireland 55 37.7 67.9 81.6 
Italy 271 29.7 54.1 67.6 
Latvia 37 30.8 56.4 69.2 
Lithuania 39 39.3 44.6 62.5 
Luxembourg 56 21.4 53.6 75.0 
Malta 56 38.7 65.3 79.8 
Netherlands 124 33.3 22.2 61.1 
Norway 18 30.4 46.4 62.3 
Poland 69 39.4 73.4 80.3 
Portugal 203 28.0 55.9 72.0 
Romania 93 22.9 50.0 73.0 
Slovakia 48 42.2 57.8 62.2 
Slovenia 45 37.9 61.5 62.1 
Spain 182 26.2 65.6 68.9 
Sweden 61 35.4 63.4 75.6 
UK 82 29.4 59.8 68.6 
          
       Data from the Article 57 database 
 
 
 
 
 
  
 
 
 
 
 
FIGURE LEGENDS 
 
Figure 1. Proportion of total fluoroquinolone prescribing for the treatment of A) 
LRTI, B) URTI, and C) UTI and for the milder infections of acute bronchitis, 
acute sinusitis and uncomplicated UTI in France, Germany and the UK. 
LRTI=Lower respiratory tract infection. URTI=upper respiratory tract infection. UTI=urinary tract infection. 
uUTI=uncomplicated UTI. 
 
Figure 2. Proportion of total fluoroquinolone prescribing for the treatment of 
the remaining indication groups in France, Germany and the UK. 
GI=gastrointestinal. 
 
Figure 3. Trends in systemic fluoroquinolone prescribing by indication in 
France, Germany and the UK. 
LRTI/URTI=lower/upper respiratory tract infection. GI=gastrointestinal infection. UTI=urinary tract infection. 
Analyses based upon own calculation. 
 
Figure 4. Trends in fluoroquinolone prescribing for acute bronchitis, acute 
sinusitis and uncomplicated UTI in France, Germany and the UK.  
Medium grey diamond = Uncomplicated UTI. Dark grey square = Acute bronchitis. Light grey triangle = Acute 
sinusitis. Analyses based upon own calculation. 
 
 
